Endobronchial ultrasound (EBUS) guided biopsy has rapidly become an indispensable tool for lung cancer staging and diagnosis of mediastinal lymphadenopathy. With its ability to safely sample mediastinal and hilar lymph nodes as well as masses adjacent to the proximal airways, EBUS has reshaped the practice of pulmonary medicine and oncology over the last decade.
What is EBUS biopsy?
EBUS biopsy utilizes a thin, flexible bronchoscope equipped with a miniature ultrasound transducer at its distal end. By emitting high frequency sound waves and detecting their reflections, the transducer is able to produce real-time images of the central airways, hilar and mediastinal structures outside the range of traditional bronchoscopy. Under ultrasound guidance, fine needle aspiration (FNA) or core biopsy needles can be precisely guided to targets detected by EBUS, allowing safe, minimally invasive tissue sampling. No radiation exposure is involved, distinguishing EBUS biopsy from mediastinoscopy or other surgical staging techniques.
The procedure is performed as an outpatient in most cases, utilizing moderate conscious sedation. After local anesthesia, the Endobronchial Ultrasound Biopsy scope is passed nasally or orally into the trachea and mainstem bronchi. Lymph nodes of interest are systematically evaluated with the ultrasound transducer, which can identify nodes as small as 5mm. Under real-time ultrasound visualization, the biopsy needle is advanced through the working channel of the bronchoscope and into target nodes or masses, with rapid on-site evaluation by cytopathology to confirm adequate lesion sampling. Multiple targets can be biopsied in a single session to maximize staging information obtained.
Impact on lung cancer diagnosis and staging
EBUS biopsy has radically changed the standard of care for lung cancer staging. Mediastinal lymph node metastasis is the most important prognosticator in lung cancer, and mediastinoscopy was previously the gold standard for mediastinal staging. However, EBUS has proven much more sensitive for detecting mediastinal lymph node involvement compared to CT alone. Three large randomized controlled trials demonstrated EBUS biopsy is more accurate and has a better safety profile compared to mediastinoscopy for mediastinal staging of non-small cell lung cancer.
As a result, guidelines now recommend EBUS biopsy as the preferred initial test for mediastinal staging in most lung cancer patients prior to surgical resection. Obtaining a tissue diagnosis and nodal staging with a single minimally invasive outpatient procedure has improved lung cancer management by avoiding unnecessary surgeries in those with metastatic disease. It has led to better preoperative selection of surgical vs non-surgical treatment strategies while sparing patients from open mediastinoscopy in many cases. The high sensitivity of EBUS for N2/N3 nodal disease means it finds metastatic nodes that used to be missed by other tests.
Role in sarcoidosis and other diseases
While lung cancer diagnosis is its most common application, EBUS biopsy also yields important information for many other pulmonary conditions involving the proximal airways and mediastinum. Granulomatous lymphadenitis due to sarcoidosis is readily diagnosed with EBUS FNA, avoiding more invasive procedures to sample accessible lymph nodes. It allows clinicians to follow the activity of sarcoidosis over time by repeat biopsy if needed. EBUS also helps diagnose tuberculosis lymphadenitis, fungal infections, and lymphoproliferative disorders involving the mediastinum. Real-time ultrasound enables precise localization and targeting of hilar or mediastinal masses, facilitating a tissue diagnosis when other modalities have failed.
Additionally, EBUS biopsy plays an essential role in diagnosing parenchymal lung lesions that are immediately adjacent to central airways but not reachable by traditional bronchoscopy due to their distance from an airway lumen. The close proximity of these lesions to the airways makes them readily identifiable on EBUS imaging and accessible to biopsy under real-time ultrasound guidance. Overall, since its introduction EBUS has been validated as a minimally invasive method to diagnose a wide variety of intrathoracic diseases beyond just lung cancer by providing crucial histologic and cytologic sampling of mediastinal and hilar structures in real-time.
Continued technical improvements
As experience with EBUS biopsy has grown, so have refinements to the technique evolved. Newer EBUS bronchoscopes feature color Doppler and high definition imaging for improved lesion conspicuity and needle guidance. Fine needle aspiration has given way to rapid on-site evaluation of core biopsies as the preferred method of assessing specimen adequacy due to its higher diagnostic yield. Electromagnetic needle tracking systems are currently under investigation to potentially automate the biopsy procedure and increase precision of needle targeting. Additional innovations may allow therapeutic interventions such as fiducial placement, brachytherapy, and ablation of lesions under real-time ultrasound control. Such technological improvements serve to further increase the power and versatility of this highly accessible minimally invasive test, which will likely remain a mainstay of pulmonology practice for decades to come.
Endobronchial ultrasound guided biopsy has revolutionized the diagnosis and treatment of lung disease since its introduction merely 15 years ago. By providing real-time ultrasound imaging and minimally invasive biopsy capabilities extending well beyond the range of standard bronchoscopy, EBUS has dramatically changed lung cancer staging algorithms, established new standards for sarcoidosis evaluation, and enabled safe diagnosis of previously inaccessible intrathoracic lesions. As technology further enhances its utility, EBUS biopsy promises to continue transforming pulmonary medicine through the ability to visualize, characterize, sample, and even treat intrathoracic pathology in an outpatient setting with low risk. Its widespread adoption underscores EBUS as one of the most important diagnostic bronchoscopic innovations of the past generation.
Get More Insights On This Topic: Endobronchial Ultrasound Biopsy
Endobronchial valves were developed primarily by the start-up medical device company Emphasys Medical (now Pulmonx - Redwood City, California) as a minimally invasive alternative to lung volume reduction surgery for emphysema.
In lung volume reduction surgery, a surgeon cuts into a patient's chest and cuts out one or more diseased portion(s) of a lung.
Endobronchial valves were designed to replicate the effects of that procedure without requiring incisions, by simply allowing the most diseased portions of the lung to collapse.
Emphasys was purchased by Pulmonx in 2009Chronic obstructive pulmonary disease (COPD) is a widespread, progressive lung disease for The global endobronchial valves market which pulmonologists in the US have had few new treatment options available outside the standard pharmacological therapies, lung rehabilitation and high-risk lung volume reduction surgery.
Now emerging technologies, in particular, endobronchial valves, which aim to shrink hyperinflated lungs in severe emphysema patients, could soon become the first minimally invasive treatment option available in the US.The major factor expected to drive the growth of the endobronchial valves market is growing awareness regarding procedure for bronchoscopic lung volume reduction in various lung-related diseases.
The increasing prevalence of tobacco smoking worldwide is consequently expected to contribute to the growth of the endobronchial valves market.
